Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | NRAS Q61K |
Therapy | Ravoxertinib |
Indication/Tumor Type | anaplastic thyroid carcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NRAS Q61K | anaplastic thyroid carcinoma | sensitive | Ravoxertinib | Preclinical - Cell culture | Actionable | In a preclinical study, Ravoxertinib (GDC-0994) inhibited viability of an anaplastic thyroid carcinoma cell line harboring NRAS Q61K in culture (PMID: 38728872). | 38728872 |
PubMed Id | Reference Title | Details |
---|---|---|
(38728872) | The ERK inhibitor GDC-0994 selectively inhibits growth of BRAF mutant cancer cells. | Full reference... |